Intrinsic Capacity — the World Health Organization's term for the sum of a person's physical and mental abilities — is assessed today through clinical and functional tests, not blood work. But researchers are now probing whether molecular markers, especially epigenetic and inflammatory aging biomarkers, could one day offer a more objective, quantitative readout of the same underlying biology. A 2026 study published in JAMA Network Open by Rouch and colleagues found that accelerated epigenetic and inflammatory aging tracked with lower intrinsic capacity, hinting at a future in which a blood sample might flag functional decline before it becomes visible in a clinic. That future, however, remains firmly in the research phase.
Understanding Intrinsic Capacity: A WHO Concept
For decades, medicine measured aging largely by the diseases a person had accumulated. The WHO's concept of Intrinsic Capacity inverts that framing: instead of asking what is wrong with you, it asks what you can still do. Stanford neuroscientist Tony Wyss-Coray, whose lab studies biological aging, compares the concept to a molecular target. "Intrinsic capacity asks, What can you do, given your age? How fast can you walk? How much weight can you lift?" he explained in a Stanford Medicine explainer on biological versus chronological age. "It's really a reflection of how functional you are, given your age. And that's what we're trying to capture at a molecular level."
Wyss-Coray says he thinks of biological clocks as a way to capture someone's functional health in a more reproducible, quantitative way — the same goal the WHO pursues with its functional measure, which gauges cognition, mobility, energy and mood, among other factors. A review of recent advances in the field, published in PMC, frames Intrinsic Capacity as a reflection of an individual's biological aging process, and notes that its evaluation may provide an innovative mechanism for encouraging adults to adopt healthy lifestyles. Identifying biomarkers of capacity decline, that review adds, could offer simple and objective measurements of biological age and health status, and guide strategies to minimize decline — even delaying progress toward disability.
Current Clinical Assessment of Intrinsic Capacity
Today, Intrinsic Capacity is measured the old-fashioned way: by testing what a person can actually do. The WHO's Integrated Care for Older People (ICOPE) guidelines define five domains — cognition, mobility, vitality, psychological well-being and sensory function — and researchers operationalize them with a mix of self-reported measures, physical measurements and cognitive assessments. A 2025 Scientific Reports study by Mary Carlota Bernal and colleagues, which modeled capacity trajectories using U.S. Health and Retirement Study data, mapped survey variables onto all five ICOPE domains, including operationalizing the Mini-Mental State Examination for cognition.
Research programs go further. The HealthAge study, described by Sophie Guyonnet, Claudie Hooper, Bruno Vellas and co-authors in GeroScience, performs a full battery of clinical tests on its INSPIRE-T human cohort to capture capacity, adding dual-energy X-ray absorptiometry for body composition at baseline and year two, and whole-body and brain MRI in a subset of 113 participants. The point of this depth is not just description: the program's stated aim is to probe the biology underlying capacity, with biospecimens collected in parallel for biomarker discovery. Even so, the PMC review cautions that additional validation studies with larger sample sizes are needed to find pragmatic ways to implement ICOPE screening across varied contexts.
The Promise of Molecular Biomarkers for Intrinsic Capacity
The gap between what a functional test shows and what the body's molecular machinery is doing is where the emerging science lives. The HealthAge program explicitly lists biomarkers among its keywords and is collecting biospecimens precisely to identify molecular markers linked to healthy and rapid aging. The ambition, as Wyss-Coray puts it, is to capture functional health "at a molecular level" — a more reproducible, quantitative complement to walking-speed tests and questionnaires.
Related work is already yielding candidate markers. Reporting in Inside Precision Medicine, Chris Anderson described research by Gurkar and colleagues on metabolomic signatures of biological aging, with future plans to study younger people's metabolomes over time in pursuit of a blood test that could predict susceptibility to age-related diseases. That effort sits in the same translational space as the capacity-biomarker search: turning aging biology into a measurable, and eventually actionable, readout.
Key Biomarker Categories: Epigenetic and Inflammatory Markers
The most direct evidence linking molecular markers to Intrinsic Capacity comes from the 2026 JAMA Network Open study by Rouch and colleagues, part of the IHU HealthAge INSPIRE/Open Science group. The study examined epigenetic aging — changes in DNA methylation patterns that serve as "biological clocks" — alongside inflammatory aging, and found that participants exhibiting accelerated aging in both pathways experienced the greatest functional impairment. That pattern suggests multiple biological aging pathways may contribute to declining health rather than a single clock telling the whole story.
Two findings add nuance. The association between accelerated epigenetic aging and lower intrinsic capacity was observed predominantly among male participants, and among the individual domains assessed, mobility appeared to be the most vulnerable to accelerated biological aging. The study's authors, as reported by the European Medical Journal, suggest that biomarkers derived from epigenetic aging — and to a lesser extent inflammatory aging — could help guide targeted interventions aimed at preserving capacity before irreversible deterioration occurs. Rather than diagnosing disease after symptoms emerge, biological aging clocks may let clinicians identify at-risk individuals earlier in the aging process, an approach aligned with the broader shift toward function-centered care and personalized prevention.
Clinical vs. Molecular: Two Approaches to Intrinsic Capacity Assessment
The clearest way to see where the field stands is to put the two approaches side by side. The table below contrasts the established clinical evaluation with the molecular research that aims to predict the same outcomes from biospecimens.
| Dimension | Clinical Assessment of Intrinsic Capacity | Molecular Biomarker Research for Intrinsic Capacity |
|---|---|---|
| Assessment type | Multi-domain clinical evaluations following WHO ICOPE guidelines, covering cognition, mobility, vitality, mood and sensory function | Exploratory analysis of biospecimens for molecular markers of biological aging |
| Examples of measures | Self-reported measures, physical measurements, cognitive tests such as the MMSE; research cohorts add DXA body-composition scans and whole-body/brain MRI | Epigenetic aging clocks and, to a lesser extent, inflammatory aging biomarkers |
| Purpose | Gauge an individual's functional health, identify decline, and encourage healthy lifestyles | Identify individuals at greater risk of functional decline earlier, and support precision-medicine interventions |
| Current status | Standard practice guided by WHO recommendations, though further validation studies are needed for pragmatic implementation | Research phase only; specific research on capacity biomarkers is rare, and validation is required before routine clinical use |
The comparison makes the boundary explicit: the clinical column describes what a clinician can do today under WHO guidance, while the molecular column describes a goal, not a product. The two are complementary rather than competing — the JAMA study's own framing envisions combining biological age measurements with functional assessment to personalize interventions that extend health span.
Limitations and Future Outlook for Biomarkers in Clinical Practice
Realistic expectations matter here. The PMC review is blunt about the state of the field: research on the identification of Intrinsic Capacity biomarkers is rare. The JAMA study's authors and the European Medical Journal's coverage agree that further validation will be required before these biomarkers can be routinely integrated into clinical practice. And a 2025 Scientific Reports paper by Bernal and colleagues flags a related caution from the digital-biomarker world — data reliability, complexity in interpreting results, limited technological accessibility and privacy concerns must all be addressed before technology-driven measures reach their potential.
None of this diminishes the direction of travel. The 2026 findings demonstrate how advances in molecular aging technologies may help reshape healthy-aging strategies, shifting care from treating age-related disease toward preserving function. But for now, no molecular test has been validated to measure Intrinsic Capacity in routine care, and commercially marketed biological-age tests are a separate matter from the research programs described here.
Navigating the Future of Intrinsic Capacity Measurement
Readers should understand that while clinical assessments of Intrinsic Capacity are currently the standard for evaluating healthy aging, molecular biomarkers represent a promising but still experimental frontier. The practical takeaway is a two-track view: functional assessment remains the validated tool, and epigenetic and inflammatory markers are the leading research candidates to make that assessment more objective and earlier. The measurable indicator to watch is the development and validation of new molecular biomarker panels for Intrinsic Capacity, and their eventual integration into clinical guidelines — a milestone that, on current evidence, has not yet arrived.
Sources
- Biological age versus chronological age: What the science says — News Center
- Intrinsic Capacity in Older Adults: Recent Advances - PMC
- A functional approach to model intrinsic capacity in ageing trajectories - Scientific Reports — Nature
- HealthAge: evaluation of intrinsic capacity changes in humans, mice, and killifish to… — SpringerLink
- Molecular Markers of Healthy and Rapid Aging Discovered — Inside Precision Medicine
- Epigenetic Aging Biomarkers Could Advance Healthy Longevity — European Medical Journal
